Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Page 1
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Murthy HS, et al. Among authors: kalaycio m. Transplant Cell Ther. 2022 Apr;28(4):187.e1-187.e10. doi: 10.1016/j.jtct.2022.01.017. Epub 2022 Jan 23. Transplant Cell Ther. 2022. PMID: 35081472 Free PMC article.
T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. Previous studies of allogeneic hematopoietic cell transplantation (alloHCT) for T-PLL are limited by small numbers, and descriptions of patie …
T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. P …
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS. Saygin C, et al. Among authors: kalaycio me. Blood Adv. 2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925. Blood Adv. 2019. PMID: 31869410 Free PMC article.
Patients who were eligible for hematopoietic cell transplantation had improved long-term survival. Collectively, our results support t-ALL as a distinct entity based on its biologic and clinical features....
Patients who were eligible for hematopoietic cell transplantation had improved long-term survival. Collectively, our results support …
Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma.
El-Asmar J, Rybicki L, Bolwell BJ, Kharfan-Dabaja MA, Dean R, Hamilton BK, Hanna R, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Hill BT, Majhail NS. El-Asmar J, et al. Among authors: kalaycio m. Biol Blood Marrow Transplant. 2019 Dec;25(12):2522-2526. doi: 10.1016/j.bbmt.2019.09.012. Epub 2019 Sep 13. Biol Blood Marrow Transplant. 2019. PMID: 31525493 Free PMC article. Clinical Trial.
Standardized mortality ratio (SMR) was significantly higher than an age-, gender-, and race-matched general population, with the magnitude of SMR decreasing as the landmark time increased (4.0 for 1-year, 3.0 for 2-year, 2.4 for 3-year, and 1.8 for 5-year survivors). Our study pr …
Standardized mortality ratio (SMR) was significantly higher than an age-, gender-, and race-matched general population, with the magnitude o …
Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation.
Patel SS, Rybicki LA, Corrigan D, Bolwell B, Dean R, Liu H, Gerds AT, Hanna R, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Majhail NS, Hamilton BK. Patel SS, et al. Among authors: kalaycio m. Biol Blood Marrow Transplant. 2018 May;24(5):1029-1034. doi: 10.1016/j.bbmt.2018.01.016. Epub 2018 Jan 31. Biol Blood Marrow Transplant. 2018. PMID: 29369800 Free PMC article.
Although day +100 survival among allogeneic hematopoietic cell transplantation (HCT) recipients has improved over time, longer-term survival remains a challenge. The aim of this study was to identify prognostic factors for survival among patients surviving longer than 100 …
Although day +100 survival among allogeneic hematopoietic cell transplantation (HCT) recipients has improved over time, longer-term s …
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.
Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Gerds AT, et al. Among authors: kalaycio m. Biol Blood Marrow Transplant. 2017 Jun;23(6):971-979. doi: 10.1016/j.bbmt.2017.03.014. Epub 2017 Mar 10. Biol Blood Marrow Transplant. 2017. PMID: 28288952 Free PMC article.
For some individuals who lack a matched sibling or unrelated donor, UCBT can result in long-term DFS; however, the success of UCBT in this population is hampered by a high rate of TRM....
For some individuals who lack a matched sibling or unrelated donor, UCBT can result in long-term DFS; however, the success of UCBT in …
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Hochhaus A, et al. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. N Engl J Med. 2017. PMID: 28273028 Free PMC article. Clinical Trial.
METHODS: In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed CML in the chronic phase to receive either imatinib or interferon alfa plus cytarabine. Long-term analyses included overall survival, response to treatm …
METHODS: In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed CML in the chronic …
Your patient has chronic leukemia: Now what?
Kalaycio M. Kalaycio M. Cleve Clin J Med. 2016 Aug;83(8):575-81. doi: 10.3949/ccjm.83gr.16002. Cleve Clin J Med. 2016. PMID: 27505878 Free article. Review.
Although still in their infancy, biologic therapies for hematologic cancers are making rapid strides, diminishing the role of chemotherapy and offering long-term remission. More patients are surviving cancer and therefore are increasingly being seen by primary care physici …
Although still in their infancy, biologic therapies for hematologic cancers are making rapid strides, diminishing the role of chemotherapy a …
Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.
Mukherjee S, Kalaycio M. Mukherjee S, et al. Among authors: kalaycio m. Curr Hematol Malig Rep. 2016 Apr;11(2):86-93. doi: 10.1007/s11899-016-0304-7. Curr Hematol Malig Rep. 2016. PMID: 26932346 Review.
TKIs along with allogeneic hematopoietic cell transplantation are conventional strategies in managing these patients but there are very few long-term survivors. Advanced phase CML represents the new frontier for CML treatment where research is critically needed to improve …
TKIs along with allogeneic hematopoietic cell transplantation are conventional strategies in managing these patients but there are very few …
Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation.
Fu S, Rybicki L, Abounader D, Andresen S, Bolwell BJ, Dean R, Gerds A, Hamilton BK, Hanna R, Hill BT, Jagadeesh D, Kalaycio ME, Liu HD, Pohlman B, Sobecks RM, Majhail NS. Fu S, et al. Among authors: kalaycio me. Bone Marrow Transplant. 2015 Oct;50(10):1326-30. doi: 10.1038/bmt.2015.166. Epub 2015 Jul 20. Bone Marrow Transplant. 2015. PMID: 26191953
The relationship of socioeconomic status (SES) with long-term outcomes in allogeneic hematopoietic cell transplantation (HCT) survivors has not been well described. ...In allogeneic HCT survivors who survive in remission for at least 1 year, SES is associated with long- …
The relationship of socioeconomic status (SES) with long-term outcomes in allogeneic hematopoietic cell transplantation (HCT) survivo …
22 results